Rare case of rilpivirine-induced severe allergic hepatitis

Y. Ahmed, W. Siddiqui, C. B. Enoch, H. Albrecht, P. B. Bookstaver
2012 Journal of Antimicrobial Chemotherapy  
were above the target level (150 ng/mL) in all patients. On a presumptive basis, the pharmacokinetic exposure of the raltegravir dose of 400 mg once daily seen in our patients in association with atazanavir/ritonavir might be sufficient to provide adequate antiretroviral coverage in an induction-maintenance strategy; should this drug combination prove to be successful in a clinical study, it would enable a reduction in both N/NtRTI-related toxicity and drug expenditure.
doi:10.1093/jac/dks400 pmid:23065700 fatcat:kzjtrgdwuncutlfgqy2rmbznry